450 related articles for article (PubMed ID: 32023731)
1. [Therapy-related myeloid neoplasms after successful treatment for acute promyelocytic leukemia: a report of four cases and literature review].
Wang Z; Xu MZ; Chen YF; Xue F; Zhang L; Hu YM; Li CW; Li SZ; Wang JX; Mi YC
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1008-1014. PubMed ID: 32023731
[No Abstract] [Full Text] [Related]
2. Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia.
Batzios C; Hayes LA; He SZ; Quach H; McQuilten ZK; Wall M; Campbell LJ
Am J Hematol; 2009 Nov; 84(11):715-9. PubMed ID: 19806661
[TBL] [Abstract][Full Text] [Related]
3. [Clinical characteristics and prognosis of patients with therapy-related myelodysplastic syndrome and acute myeloid leukemia arising from malignant tumors].
Xu XS; Ding H; Zhang X; Liao Y; Li H; Liu QY; Liu JZ; Zhang L; Huang J; Gong YP; Ma HB; Xiang B; Dai Y; Hou L; Shuai X; Niu T; Wu Y
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):742-748. PubMed ID: 38049318
[No Abstract] [Full Text] [Related]
4. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Xu SN; Chen JP; Liu JP; Xia Y
Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
[TBL] [Abstract][Full Text] [Related]
5. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem.
Latagliata R; Petti MC; Fenu S; Mancini M; Spiriti MA; Breccia M; Brunetti GA; Avvisati G; Lo Coco F; Mandelli F
Blood; 2002 Feb; 99(3):822-4. PubMed ID: 11806982
[TBL] [Abstract][Full Text] [Related]
6. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F
Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912
[TBL] [Abstract][Full Text] [Related]
7. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy.
Montesinos P; González JD; González J; Rayón C; de Lisa E; Amigo ML; Ossenkoppele GJ; Peñarrubia MJ; Pérez-Encinas M; Bergua J; Debén G; Sayas MJ; de la Serna J; Ribera JM; Bueno J; Milone G; Rivas C; Brunet S; Löwenberg B; Sanz M
J Clin Oncol; 2010 Aug; 28(24):3872-9. PubMed ID: 20625122
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.
Leoni F; Gianfaldoni G; Annunziata M; Fanci R; Ciolli S; Nozzoli C; Ferrara F
Haematologica; 2002 May; 87(5):485-9. PubMed ID: 12010661
[TBL] [Abstract][Full Text] [Related]
9. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
10. [Acute promyelocytic leukemia: state-of-the-art management].
Asou N
Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
Aribi A; Kantarjian HM; Estey EH; Koller CA; Thomas DA; Kornblau SM; Faderl SH; Laddie NM; Garcia-Manero G; Cortes JE
Cancer; 2007 Apr; 109(7):1355-9. PubMed ID: 17326049
[TBL] [Abstract][Full Text] [Related]
12. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J
Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience.
Lobe I; Rigal-Huguet F; Vekhoff A; Desablens B; Bordessoule D; Mounier C; Ferrant A; Sanz M; Fey M; Chomienne C; Chevret S; Degos L; Fenaux P;
Leukemia; 2003 Aug; 17(8):1600-4. PubMed ID: 12886249
[TBL] [Abstract][Full Text] [Related]
14. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia.
Thomas X; Dombret H; Cordonnier C; Pigneux A; Gardin C; Guerci A; Vekhoff A; Sadoun A; Stamatoullas A; Fegueux N; Maloisel F; Cahn JY; Reman O; Gratecos N; Berthou C; Huguet F; Kotoucek P; Travade P; Buzyn A; de Revel T; Vilque JP; Naccache P; Chomienne C; Degos L; Fenaux P
Leukemia; 2000 Jun; 14(6):1006-13. PubMed ID: 10865965
[TBL] [Abstract][Full Text] [Related]
15. The impact of molecularly targeted therapies upon the understanding of leukemogenesis and the role of hematopoietic stem cell transplantation in acute promyelocytic leukemia.
Nagai S; Takahashi T; Kurokawa M
Curr Stem Cell Res Ther; 2010 Dec; 5(4):372-8. PubMed ID: 20528759
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of Arsenic Trioxide Combined with ATRA and Chemotherapy for Relapsed Acute Promyelocytic Leukemia Patients].
Li Y; Liu KQ; Gong BF; Wang Y; Wei H; Lin D; Liu BC; Zhou CL; Wei SN; Zhang GJ; Liu YT; Gong XY; Wang JX; Mi YC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):1-6. PubMed ID: 32027244
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
[TBL] [Abstract][Full Text] [Related]
18. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
[TBL] [Abstract][Full Text] [Related]
19. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
20. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
